Systematic Light Exposure for Pediatric Brain Tumor Survivors

This study is looking at whether using bright light exposure can help children and teenagers, aged 10 to 18, who have been treated for a brain tumor. Many survivors experience tiredness (fatigue) and problems with thinking (cognitive symptoms) like slow processing or trouble paying attention. This study will compare daily use of special bright light glasses (Luminette Version 3) to dim light glasses over 6 weeks. Researchers will check if the bright light helps with fatigue, sleep, and mood. This is a small pilot study with 40 participants to see if this approach is promising for future, larger studies. To join, you must have been treated for a brain tumor at Texas Children's Hospital and meet other specific criteria.

Study design
This is an interventional study with 40 planned participants. Participants will be randomly assigned to either the bright light group or the dim light group.
What's involved
You would use special light glasses for up to 30 minutes each weekday for 6 weeks. You would also complete cognitive assessments and questionnaires at the start, Week 4, Week 6, and Week 8.
Compensation
Not stated in the trial record.
Follow-up
Assessments will be completed up to 2 weeks after the intervention ends (Week 8).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05340881

Systematic Light Exposure in Pediatric Brain Tumor Survivors

Recruiting
NAAges 10–18InterventionalSupportive care
Baylor College of Medicine
~40 participants
Updated 2025-09-18 on ClinicalTrials.gov
What's tested:Bright Light ExposureDim Light ExposureCognitive Assessment

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent of approached participants who consent to study participation
Measured over Once, prior to enrollment
+2 more outcomes measured
Brain Tumor
1 sites across 1 states
Texas1
  • Kimberly P Raghubar, PhD · PRINCIPAL_INVESTIGATOR · Baylor College of Medicine
  • Heather M Conklin, PhD · PRINCIPAL_INVESTIGATOR · St. Jude Children's Research Hospital

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosed and treated for a brain tumor at Texas Children's Hospital
Treated with either surgery only or surgery and proton beam radiation therapy
Treated for tumors other than high-grade gliomas, brain stem gliomas, or atypical teratoid rhabdoid tumors given associated reduced survival rates
Currently or previously enrolled in longitudinal studies of neurocognitive outcomes in survivors of pediatric brain tumor (Lisa Kahalley, PI; H-29026, H-35681, H-40804, H-40961, H-49380, H-26785, H-41705
Ages 10-18 years
At least 1 year post-diagnosis
Endorsed mild to moderate symptoms of fatigue on the PROMIS
Approval from Long-Term Survivorship provider
Adequate vision for computerized tasks
English-speaking
Intelligence Quotient (IQ) above 70

Exclusion

Diagnosis and/or treatment for secondary malignancy in the past 12 months
Current or previous (within 12 months) suicidal ideation or severe depression requiring immediate intervention
Presence of photophobia or other eye diseases, seizures, and/or migraines
Use of photosensitizing medications
Current or previous use of light therapy
  • Percent of approached participants who consent to study participationOnce, prior to enrollment

    The rates of study participation and related 90% Blyth-Still-Casella intervals, as well as their regular 90% confidence interval, will be estimated. Test of one proportion will be performed against an estimated rate of 70%. The rate will be evaluated for the group as a whole as well as separately for the bright light intervention and placebo-control groups.

  • Percent of sessions completed during all 6 weeks of bright or dim light exposureAt completion of bright or dim light exposure (Week 6)

    The rates of light intervention adherence and related 90% Blyth-Still-Casella intervals, as well as their regular 90% confidence interval, will be estimated. Test of one proportion will be performed against an estimated rate of 77% of sessions completed on average. The rate will be evaluated for the group as a whole as well as separately for the bright light intervention and placebo-control groups.

  • Percent of participants rating the intervention as acceptable by indicating that they would recommend this intervention to other survivors.Once, at completion of intervention (Week 6)

    The rates of completion of cognitive assessments and related 90% Blyth-Still-Casella intervals, as well as their regular 90% confidence interval, will be estimated. Test of one proportion will be performed against an estimated rate of 75%. The rate will be evaluated for the group as a whole as well as separately for the bright light intervention and placebo-control groups.